Pitango HealthTech – which is Pitango VC’s dedicated healthcare fund – recently announced the first closing of its second dedicated healthcare fund Pitango HealthTech II. And Pitango HealthTech II, a $175 million fund, will be dedicated to investing in entrepreneurs utilizing data science, AI, medical devices, and novel biology at the forefront of healthcare transformation. The $9 trillion global healthcare market is undergoing dramatic shifts, and Israeli entrepreneurs are building companies that are spearheading this transition.
Pitango HealthTech II invests in healthcare innovation, including the decentralization of healthcare, personalized medicine, medical devices and diagnostics, and artificial intelligence, software, and data infrastructure.
Pitango HealthTech invests in companies from the seed stage to the commercial stage. And the fund’s investment strategy is focused on all segments of healthcare and life sciences. Previous investments include value-driving companies such as Protai, Laguna Health, Vertos, Visby, Clew, and Magenta. The first investments with the newest fund are QuantHealth.ai, an AI company focused on clinical trial simulations to accelerate and de-risk drug development, and Nevia Bio, a FemTech company developing an AI-based biomarker platform for early detection of women’s health diseases.
Pitango’s HealthTech team is made up of Ittai Harel (Managing Partner), Hila Karah (Managing Partner), Dr. Jonathan Glazer (Partner), Joel Schoppig (Senior Principal), and Dr. Seth Rudnick (Special Advisor). And Pitango HealthTech is committed to promoting diversity within the healthcare technology space, upholding ESG standards, and ensuring women founders in the domain receive the same access to investment opportunities. Since being founded in 1993, Pitango has invested in over 250 companies and seen more than 85 become publicly traded companies or acquired by strategic players.
KEY QUOTES:
“Despite the global and local macroeconomic challenges, the healthcare sector continues to show resilience and growth. Recent events such as the pandemic, decentralization of healthcare, and value-based care, have resulted in unprecedented openness towards the adoption of new technologies. We’re launching this new fund to continue to back entrepreneurs and invest in companies that are revolutionizing the healthcare industry. Pitango believes that the most promising healthcare innovations occur at the convergence of life science and medical technologies with data science and AI, coupled with innovative services. This revolution is at its early onset and is yet to accelerate.”
— Ittai Harel, Managing Partner at Pitango HealthTech
“The current environment offers great investment opportunities for health tech investors. Our team has decades of experience working with global healthcare providers, payers, medical device and pharma companies. We garner this expertise to support our portfolio companies from inception to scale. We’re seeing an incredible generation of companies being formed right now and are looking forward to working with the best of them.”
— Hila Karah, Managing Partner at Pitango HealthTech
“Pitango has been a key player in the healthcare ecosystem in Israel since its inception. Over the last three decades, we’ve had the opportunity to invest in over 50 healthcare companies and see 15 of them exit successfully and many others on a strong growth trajectory. It’s a track record we’re proud of and that gives us the confidence to double down with a second dedicated healthcare fund.”
— Rami Kalish, Managing Partner and Co-Founder at Pitango
